MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead, Merck & Co. to Evaluate Lung Cancer Combo Therapy in Two Clinical Studies

01/10/2022 | 11:11pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 1.08% 64.35 Delayed Quote.-11.38%
MERCK & CO., INC. 0.86% 94.64 Delayed Quote.22.43%
ON SEMICONDUCTOR CORPORATION -2.49% 54.5 Delayed Quote.-19.76%
All news about MERCK & CO., INC.
05/24Merck & Company Declares Quarterly Cash Dividend of $0.69 a Share, Payable July 8 to St..
MT
05/24Merck Announces Third-Quarter 2022 Dividend
BU
05/24Merck's Keytruda Receives European Commission Approval for Breast Cancer
MT
05/24European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant..
BU
05/24Merck Gets EU Approval of Expanded Keytruda Use in Breast Cancer
DJ
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positiv..
MT
05/23Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) as Adjuvant Treatm..
AQ
05/23Merck & Co. Plans $470 Million Investment In Manufacturing Facilities In Ireland
MT
05/20Merck's Keytruda Receives Positive EMA Panel Opinion as Adjuvant Therapy in Skin Cancer
MT
05/20Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treat..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 57 865 M - -
Net income 2022 15 235 M - -
Net Debt 2022 17 730 M - -
P/E ratio 2022 15,6x
Yield 2022 2,94%
Capitalization 239 B 239 B -
EV / Sales 2022 4,44x
EV / Sales 2023 4,38x
Nbr of Employees 67 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 94,64 $
Average target price 96,04 $
Spread / Average Target 1,48%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.22.43%237 278
JOHNSON & JOHNSON6.04%472 179
PFIZER, INC.-9.55%296 704
ROCHE HOLDING AG-14.40%273 052
ELI LILLY AND COMPANY10.77%272 388
ABBVIE INC.10.13%261 585